This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: A81.8 (Other atypical virus infections of central nervous system — including kuru) | Special Copayment Reduction: V282 (severe intractable disease, 10% copayment for 5 years after registration) |
| B. Synonyms | Kuru disease, other atypical virus infections of the central nervous system, laughing sickness, cannibalism-associated prion disease of the Fore people |
| C. Adult onset | Possible first manifestation in adulthood: yes (historical) — Kuru is now a virtually eradicated disease; historically it developed in adulthood, after an incubation period of years to decades following exposure to cannibalistic practices, in adults (mainly women) of the Fore tribe of Papua New Guinea. There are currently no new cases. |
| 1. History | 1950s: Gajdusek and Zigas describe the Fore tribe of Papua New Guinea → 1966: Gajdusek succeeds in transmission to chimpanzees → 1976: Nobel Prize in Physiology or Medicine → 1982: Prusiner establishes the prion concept → 1997: Prusiner's Nobel Prize → gradual eradication after the ban on cannibalistic practices. |
| 2. Causes | Oral and transdermal transmission of the abnormal-form prion protein (PrPSc). Transmitted through the Fore funeral cannibalistic practice of eating tissues such as the brain of deceased relatives. A transmission route similar to bovine spongiform encephalopathy (BSE). |
| 3. Genetics | The PRNP gene codon 129 polymorphism (Met/Val) has a decisive influence on susceptibility to disease and on the incubation period. Val/Val homozygotes are highly resistant to kuru. A distinctive resistance genotype was selected among long-term survivors, providing evidence of adaptive evolution to kuru. |
| 4. General epidemiology | Epidemic among the Fore tribe of the Eastern Highlands province of Papua New Guinea in the 1950s-60s. About 200 deaths per year (peak in the 1950s). Declined after the ban on cannibalistic practices (late 1950s) → virtually eradicated after 1980. The last fatal case was reported around 2005. |
| 5. Pathophysiology | Oral ingestion of PrPSc → absorption from the intestinal tract → reaches the nervous system via the lymphatic system → converts normal PrPC in the brain into the abnormal form (template-directed reaction) → spongiform change and neuronal loss centered on the cerebellum and basal ganglia → formation of amyloid plaques (kuru plaques). |
| 6. Symptoms | Three stages: Stage 1 (ambulant stage) — ataxia, gait disturbance, arthralgia, headache; Stage 2 (sedentary stage) — worsening cerebellar ataxia, abnormal involuntary movements, pathological laughter (involuntary laughter, "laughing sickness"); Stage 3 (terminal stage) — inability to move, dysphagia, pressure ulcers, dementia, death. |
| 7. Signs | Signs of cerebellar ataxia (positive Romberg, inability to tandem walk). Myoclonus and tremor. Pathology: spongiform change of the cerebellum, reactive gliosis, kuru plaques (PAS-positive amyloid plaques), neuronal loss. Brain MRI: cerebellar atrophy, T2 signal changes. |
| 8. Screening | With no new cases occurring at present, screening has no practical significance. Historically, epidemiological surveillance through field surveys of the Fore tribe was used. PRNP gene testing for prion diseases in general today can be used to assess susceptibility. |
| 9. Diagnosis | Epidemiological exposure history (residence in an area with cannibalistic practices, participation in cannibalistic practices) + clinical course (cerebellar ataxia → involuntary movements → dementia) + brain pathology (kuru plaques, spongiform change). At present, confirmed by brain autopsy, immunohistochemistry, and PrPSc Western blot. |
| 10. Treatment | No curative treatment. Entirely supportive and palliative care. As there are no new patients at present, there is no need for treatment. Historically, only supportive care for symptom relief was provided, and all patients died. |
| 11. Prognosis | 100% fatal. Death within an average of 12 months (range 3 months to 3 years) after onset. No spontaneous remission reported. As the epidemic ended after the ban on cannibalistic practices, there are no new cases at present. |
| 12. Prevention | The ban on cannibalistic practices was the only and complete prevention, and it succeeded in eradication in practice. At present, adherence to standard procedures for preventing prion contamination in medical and laboratory settings is the theoretical means of prevention. General principles for preventing prion diseases (tissue handling, sterilization) apply. |
| 13. References | Gajdusek DC, Zigas V. Degenerative disease of the central nervous system in New Guinea. N Engl J Med. 1957 … and 9 other papers |
Kuru is one of the most unusual neurological diseases discovered in the 20th century, and the history of its study is directly linked to the establishment of the prion concept. "Kuru" means "trembling" or "fear" in the language of the Fore tribe living in the Eastern Highlands province of Papua New Guinea, and was the local name for a rapidly spreading progressive neurological disease in this region in the mid-1950s.
In 1957, the American neuroscientists D. Carleton Gajdusek and Vincent Zigas first reported in the scientific literature the kuru occurring in clusters in the Fore tribe. They observed patients directly in Papua New Guinea and collected clinical and epidemiological data, and described that the disease occurs mainly in women and children and has cerebellar ataxia as its main symptom. The mortality was high, and the devastation of dozens of deaths each year in affected villages was reported.
The first clue to the etiology came from epidemiological investigation. Gajdusek traced kuru to the funeral rites of the Fore tribe. The customs of the Fore tribe included ritualistic cannibalism, eating the body of a deceased relative, especially the brain, and kuru occurred in clusters among the women and children who mainly took part in this practice. In 1966, Gajdusek and Clarence Gibbs inoculated chimpanzees with brain tissue from kuru patients and, after an incubation period of about 2 years, succeeded in inducing a neurological disease similar to kuru, thereby demonstrating for the first time that kuru has a transmissible infectious etiology. For this achievement, Gajdusek received the Nobel Prize in Physiology or Medicine in 1976.
The etiology of kuru was finally elucidated in 1982 when Stanley Prusiner proposed the concept of the prion (proteinaceous infectious particle). Prusiner argued that the transmission of scrapie and Creutzfeldt-Jakob disease (CJD), including kuru, is mediated by an abnormal-form protein (PrPSc) that contains no nucleic acid, and he received the Nobel Prize in Physiology or Medicine in 1997 for this revolutionary concept. After cannibalistic practices were stopped in the late 1950s by bans from the Papua New Guinea government and churches, the occurrence of kuru declined gradually, and the last case was reported around 2005, a case with an incubation period of about 50 years. This became important epidemiological evidence demonstrating that the incubation period of prion diseases can reach several decades.
The cause of kuru is the transmission of the abnormal-form prion protein (PrPSc, scrapie isoform of prion protein). Unlike viruses, bacteria, fungi, and parasites, a prion is an infectious agent made of pure protein containing no nucleic acid (DNA or RNA). Neurotoxicity develops when PrPC (cellular isoform), a glycoprotein of the normal neuronal cell membrane, is converted into PrPSc, which has an abnormal tertiary structure (alpha-helix → beta-sheet conversion).
In kuru, the route of transmission was the ritualistic cannibalistic practice of the Fore tribe. During funeral rites in which relatives (mainly women and children) ate the brain, liver, and other organs of a deceased relative, PrPSc was ingested and absorbed orally and through mucosal wounds. Because the concentration of PrPSc is highest in brain tissue, eating brain was the main route of infection. Transdermal absorption through skin wounds or mucous membranes is also theoretically possible.
Orally ingested PrPSc is absorbed into gut-associated lymphoid tissue through the Peyer's patches of the digestive tract and reaches the central nervous system by retrograde neuronal transport or through the bloodstream. Once inside the central nervous system, PrPSc catalyzes a "template-directed refolding" reaction that uses normal PrPC as a template and converts it into the abnormal form in a chain reaction, so that the abnormal prion is amplified exponentially.
Kuru is thus classified as an "acquired transmissible prion disease" caused by ingestion of exogenous PrPSc. Similar acquired transmissible prion diseases include variant Creutzfeldt-Jakob disease (vCJD, from eating beef infected with bovine spongiform encephalopathy) and iatrogenic CJD (dura mater grafts, growth hormone injections).
Kuru is not a directly inherited disease, but polymorphisms of the host's PRNP gene (prion protein gene, chromosome 20p13) have a decisive influence on susceptibility to kuru, incubation period, and clinical features. This gene-environment interaction is one of the most important genetic findings in kuru research.
The key is the codon 129 (methionine/valine, Met/Val) polymorphism of the PRNP gene. Human codon 129 codes for methionine (M) or valine (V), and three genotypes (MM, MV, VV) are possible. Analysis of Fore deaths during the kuru epidemic showed that homozygotes (MM or VV) at codon 129 tended to have a higher incidence and a shorter incubation period, whereas heterozygotes (MV) tended to have a lower incidence and a longer incubation period. In particular, the cases that died decades after the end of the kuru epidemic (the last cases) were MV heterozygotes, suggesting that heterozygosity is a resistance factor against prion disease.
In a notable study, in 2015 Mead et al. discovered a new PRNP variant (G127V) in Fore tribe members who survived despite long exposure to kuru. This variant was shown to confer strong resistance to kuru and is interpreted to have increased selectively in the Fore tribe during the kuru epidemic through natural selection. Carriers of the G127V variant showed resistance to in vitro PrPSc conversion, so this variant provides an important clue for research on prion therapeutic targets. It is regarded as one of the most direct pieces of evidence in human history of genetic natural selection by an epidemic disease.
Kuru was an endemic disease confined to the Fore tribe and neighboring tribes living in the Eastern Highlands province of Papua New Guinea. The geographic distribution of cases coincided exactly with the areas where ritualistic cannibalistic practices were carried out.
The epidemic peaked in the 1950s, with about 200 deaths per year from kuru, and in some villages kuru was the leading cause of death in adult women. At that time there was even a demographic change in which the sex ratio of the Fore became severely imbalanced (excess female deaths in a tribe that preferred boys). The reason kuru occurred overwhelmingly in women and children is that the practice of eating high-risk parts such as the brain was carried out mainly by women and children.
After the ban on cannibalistic practices, the incidence declined markedly. Kuru did not occur in children born after 1957, and the epidemic showed a pattern of dying out as the generation exposed to cannibalistic practices aged. New cases became extremely rare after 1980, and the last officially confirmed death was around 2005. Some researchers cannot rule out the possibility that a very small number of survivors are still in the incubation period, but in practice kuru is considered eradicated.
The epidemiological study of kuru was subsequently used directly in epidemiological studies of variant CJD (vCJD). The incubation period of several decades observed in the Fore tribe and the role of the codon 129 polymorphism provided important grounds for estimating the vCJD incubation period and the number of vCJD cases in the United Kingdom.
The pathophysiology of kuru is one of the most important research subjects in modern prion biology. The process by which orally ingested PrPSc is absorbed from the gut, reaches the brain, and converts normal PrPC in a chain reaction to cause neural damage has been elucidated step by step.
Absorption stage: Orally ingested PrPSc is partially resistant to gastric acid and proteolytic enzymes (a protease K-resistant core fragment remains even after treatment of PrPSc with protease K), and enters gut-associated lymphoid tissue (GALT) through the Peyer's patches and M cells (microfold cells) of the small intestinal mucosa. In GALT, follicular dendritic cells (FDCs) temporarily store and amplify PrPSc.
Neural transmission stage: From the lymphoid tissue it travels to the central nervous system by retrograde axonal transport through the peripheral autonomic nervous system (enteric nervous system, vagus nerve, sympathetic nerves). In this process it passes through the spinal cord and brainstem and finally reaches the cerebellum and cerebrum. Most of the incubation period is presumed to be spent in this lymphoid tissue and neural transmission process.
Intracerebral amplification stage: When a small amount of PrPSc reaches the brain, it initiates self-replicating chain conversion using normal PrPC as a template. This process is explained by the "nucleation-polymerization" model. PrPSc forms aggregates, and these fragment to form new nuclei; as this process repeats, amplification is exponential. The kuru plaque characteristic of kuru is a PAS-positive amyloid plaque formed predominantly in the cerebellum and is a pathological product of PrPSc aggregates. Oligodendrocytes and neurons die from the cytotoxicity of PrPSc aggregates, and reactive astrogliosis and spongiform change progress.
The clinical course of kuru is divided into three stages (ambulant, sedentary, terminal) and is characterized by progressive neurological decline centered on cerebellar ataxia. The total duration of illness averages 12 months (range 3-36 months), relatively short compared with other prion diseases.
Stage 1 (ambulant stage): Early on, headache, arthralgia, and limb pain may appear as prodromal symptoms. Gradually cerebellar ataxia becomes prominent, and unsteady gait and balance impairment progress. Tremor appears, along with voice changes (tremulous dysarthria) and abnormal coordination of eye movements. At this stage the patient can still walk independently.
Stage 2 (sedentary stage): Ataxia worsens so that independent walking becomes impossible and even sitting without help becomes difficult. The most characteristic symptom, abnormal involuntary laughter (pathological laughter), becomes prominent at this stage, which is why the nickname "laughing sickness" arose. This involuntary laughter is a neurological phenomenon unrelated to emotional response. Severe tremor, myoclonus, and chorea-like movements also appear. Cognitive function is preserved until relatively late.
Stage 3 (terminal stage): Independent movement becomes completely impossible, and aspiration pneumonia due to dysphagia and pressure ulcers develop. In the terminal stage, dementia, urinary incontinence, and fecal incontinence appear, and in some cases consciousness is relatively preserved until just before death. Most die of pneumonia or sepsis.
Neurological signs: Signs of cerebellar ataxia (abnormal finger-nose test, abnormal heel-knee test, positive Romberg, inability to tandem walk, nystagmus) are the most prominent. Intention tremor is clearly observed in the upper limbs. Involuntary movements (myoclonus, chorea-like movements) become distinct from stage 2 onward. Deep tendon reflexes are hyperactive early and decreased in the terminal stage. Pyramidal tract signs (positive Babinski response) appear in some patients. Cognitive decline appearing relatively late distinguishes kuru from other prion diseases (in CJD, cognitive decline occurs early).
Pathological signs (brain autopsy): The most characteristic pathological finding of kuru is the kuru plaque concentrated in the cerebellum. It is an amyloid plaque that is positive on PAS (periodic acid-Schiff) staining and Congo red staining and reacts positively with PrP antibody by immunohistochemistry. These plaques are rare in CJD and are a characteristic pathological finding of kuru that distinguishes it from other prion diseases. Spongiform change, neuronal loss, and reactive astrogliosis are observed in the cerebellum, basal ganglia, thalamus, and cerebral cortex. Neuroinflammatory findings are mild.
Brain MRI: Cerebellar atrophy and T2/FLAIR signal changes in the cerebellar dentate nucleus and basal ganglia are observed. Abnormal signals may appear on diffusion-weighted imaging (DWI), but specificity is lower than in CJD.
Because there are currently no new cases of kuru, no practical screening program exists. Historically, during the period when kuru was epidemic, epidemiological surveillance (village-level tracking of occurrence, periodic visit surveys) was used in Papua New Guinea, and this played a decisive role in elucidating the epidemiology and transmission route of the disease.
From a modern perspective, PRNP gene codon 129 polymorphism analysis, developed in kuru research, is used to assess susceptibility to prion diseases in general. Codon 129 homozygotes (MM or VV) have a higher risk of prion diseases, including vCJD, than heterozygotes (MV), so PRNP gene testing may be performed when prion disease risk counseling is needed (e.g., dura mater graft recipients, those with a history of growth hormone treatment).
The RT-QuIC (real-time quaking-induced conversion) assay, developed in kuru research, is a technique that amplifies and detects extremely small amounts of PrPSc, and is now used in a groundbreaking way for early screening and diagnosis of other prion diseases such as CJD and vCJD. This can be called the clinical legacy of kuru research.
The historical diagnosis of kuru was made by a combination of epidemiological exposure history + characteristic clinical course + brain autopsy pathological findings. Because there are currently no new patients, the following describes the diagnostic criteria in a historical and academic context.
Epidemiological criteria: History of residence in a kuru-epidemic area (Eastern Highlands, Papua New Guinea) or of participation in cannibalistic practices (ritualistic cannibalism). History of contact with family members affected by kuru.
Clinical criteria: A characteristic clinical course including the three main symptoms of progressive neurological decline centered on cerebellar ataxia, involuntary laughter, and intention tremor. Unlike CJD, cognitive function is relatively preserved early on. A uniformly fatal course in which all patients die within months to years.
Pathological confirmation: Confirm cerebellar kuru plaques (PAS-positive amyloid plaques), spongiform change, neuronal loss, and gliosis at brain autopsy. Detect PrPSc by immunohistochemistry, or confirm protease K-resistant PrP fragments on Western blot. Detection of PrPSc in brain or CSF by RT-QuIC is the modern confirmatory method.
Differential diagnosis: Must be distinguished from other cerebellar ataxia diseases (spindle-body cerebellar ataxia, multiple system atrophy, parainfluenza cerebellitis), spinocerebellar degeneration, CJD, and so on. Without an epidemiological exposure history, kuru is not included in the differential list.
There was no curative treatment for kuru, and there is none now. Treatment research was attempted after kuru was identified as a transmissible prion disease, but all patients died within months to 3 years after diagnosis.
Historically, traditional medicine (magico-religious healing) of the local Fore tribe was practiced, but it was ineffective. During their field surveys, Gajdusek's team and others provided Western-medicine supportive care to some patients, but it did not change the course of the disease.
In terms of prion treatment research, various compounds (quinacrine, chlorpromazine, polyanions, anti-prion antibodies, etc.) have been studied in animal models and in vitro for kuru and other prion diseases, but no drug has established efficacy in human clinical use. Current research directions include suppression of PRNP gene expression (antisense oligonucleotides, RNAi), small-molecule PrPSc aggregation inhibitors, and immunotherapy (anti-PrP monoclonal antibodies).
The treatment given to kuru patients was entirely supportive and palliative care: nutritional support (assisted feeding in patients with dysphagia), prevention of pressure ulcers, management of aspiration pneumonia, seizure control (anticonvulsants), and pain management. Because there are no new kuru patients at present, treatment is not a practical issue.
Kuru is 100% fatal. Death after onset has been confirmed in all recorded patients, and there are no cases of spontaneous remission or long-term survival. The average survival after onset is about 12 months (range: 3 months to 3 years).
Prognosis differs by clinical stage. Progression from stage 1 (ambulant stage) to stage 2 (sedentary stage) takes place within months, and a further several months elapse from stage 2 to the terminal stage. In some patients progression seemed to slow temporarily at a particular stage, but the final outcome did not change.
The incubation period was longer (decades) in PRNP codon 129 heterozygotes (MV), and they made up the group of the last patients to develop disease after the end of the kuru epidemic. This shows that genetic background influences prognosis (incubation period and time of onset) in prion disease.
The historical importance of kuru lies less in the disease itself than in its influence on prion research. The prion transmission mechanism, the understanding of the incubation period, and the role of PRNP gene polymorphism established through kuru research were subsequently applied directly to the understanding and management of other prion diseases such as CJD, vCJD, GSS, and FFI.
The prevention of kuru is, historically, a very simple and completely successful case. The only and complete means of prevention was the ban on cannibalistic practices; after the cannibalistic practices of the Fore tribe were stopped in the late 1950s through the educational and prohibitive activities of the Papua New Guinea colonial government and religious missionaries, new kuru cases gradually decreased and disappeared completely. This is the only case in which a prion disease was eradicated by public health intervention alone.
From a modern perspective, the lessons of kuru lead to principles for preventing prion transmission. ① Preventing prion contamination in medical and laboratory settings: Because prions are resistant to ordinary disinfection and sterilization methods (formaldehyde, ultraviolet light, 70% alcohol), instruments suspected of prion contamination must be treated with 2N NaOH or with 134°C autoclave sterilization (134°C, 18 minutes, porous load cycle). ② Safety management of transplant materials: Dura mater grafts, corneal transplants, and growth hormone (pituitary-derived) are historical cases of iatrogenic CJD transmission, so recombinant growth hormone is now used and guidelines excluding donors at risk of CJD apply to tissue transplantation from brain-dead donors. ③ Preventing variant CJD: To prevent vCJD derived from BSE-infected cattle, distribution as food of BSE-risk bovine parts (specified risk materials, SRM: brain, spinal cord, eyes, tonsils, intestines, etc.) is prohibited.
Because kuru itself has been eradicated, no additional preventive measures are necessary. However, the legacy of kuru research has become the basis of modern prion disease prevention strategies.
Gajdusek DC, Zigas V. Degenerative disease of the central nervous system in New Guinea: the endemic occurrence of 'kuru' in the native population. N Engl J Med. 1957;257(20):974-978. DOI: 10.1056/NEJM195711142572005. PMID: 13483871.
Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216(4542):136-144. DOI: 10.1126/science.6801762. PMID: 6801762.
Mead S, Whitfield J, Poulter M, et al. A novel protective prion protein variant that colocalizes with kuru exposure. N Engl J Med. 2009;361(21):2056-2065. DOI: 10.1056/NEJMoa0809716. PMID: 19923577.
Collinge J, Whitfield J, McKintosh E, et al. Kuru in the 21st century — an acquired human prion disease with very long incubation periods. Lancet. 2006;367(9528):2068-2074. DOI: 10.1016/S0140-6736(06)68930-7. PMID: 16798390.
Gajdusek DC, Gibbs CJ Jr, Alpers M. Experimental transmission of a kuru-like syndrome to chimpanzees. Nature. 1966;209(5025):794-796. DOI: 10.1038/209794a0. PMID: 5922150.
Mead S, Poulter M, Uphill J, et al. Genetic risk factors for variant Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurol. 2009;8(1):57-66. DOI: 10.1016/S1474-4422(08)70265-5. PMID: 19081516.
Alpers MP. The epidemiology of kuru: monitoring the epidemic from its peak to its end. Philos Trans R Soc Lond B Biol Sci. 2008;363(1510):3707-3713. DOI: 10.1098/rstb.2008.0071. PMID: 18849290.
Liberski PP, Gajos A, Sikorska B, Lindenbaum S. Kuru, the first human prion disease. Viruses. 2019;11(3):232. DOI: 10.3390/v11030232. PMID: 30857309.
Wadsworth JD, Joiner S, Linehan JM, et al. Kuru prions and sporadic Creutzfeldt-Jakob disease prions have equivalent transmission properties in transgenic and wild-type mice. Proc Natl Acad Sci USA. 2008;105(10):3885-3890. DOI: 10.1073/pnas.0800190105. PMID: 18309120.
Zigas V, Gajdusek DC. Kuru: clinical study of a new syndrome resembling paralysis agitans in natives of the Eastern Highlands of Australian New Guinea. Med J Aust. 1957;44(21):745-754. PMID: 13483875.